GLG News by Labor Relations and Union-Management Negotiation Experts (US)

Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.

 as per an accompanying editorial "In conclusion, it is particularly gratifying that years of research in tumor biology and drug development have coalesced. Translation of these research advances into therapeutic benefits for patients with refractory thyroid cancer, and a related paradigm shift...

Genetic determinants will decrease use of some drugs due to mutations such as Kras which indicate less chance of response and thus the chemo agents will not be used.

The Columbus Dispatch published a six-part expose/overview about the diversion and sale of controlled substances. Mike Pramik, the reporter who wrote all six parts, has pulled together a must-read series. Since the Dispatch is also Cardinal Health’s (CAH) hometown paper, there are some good insights...

When faced with unprecedented lack of confidence the public is flooded with statements from Executives across the Financial Sector comparing the recent downfall of their firms to natural disasters.  Natural disasters cannot in anyway be avoided.  The use of this egregious analogy only...

Last week, Cardinal Health (CAH) announced agreements with the Drug Enforcement Adminstration (DEA) regarding its license suspensions for controlled substances. These suspensions had a negative impact on the company's sales and market position. The company even publicly apologized for its actions during...

The primary goal was improved survival- NOT REACHED!!

"U.K. Health Service Agrees to Pay for Tarceva Following the Company's Discount" so that the price is equivalent to Taxotere.

Cardinal Health (CAH) is rapidly growing its Chinese drug distribution business, while expanding manufacturing in India (but not China). This strategy is especially interesting given Cardinal’s planned separation of its supply chain division from clinical & medical products. The era of global wholesalers...

The eyes of the world are focused on Washington where the SEC, the FED and Congress debate how they are going to execute the massive bail out announced last week.  As a derivatives trader who sits in the trenches, I am more concerned about a larger issue.  Where were the Risk Managers ...